Association Between Dupilumab Effect on Nasal Polyp Score and Biomarkers of Type 2 Inflammation in Patients with Chronic Rhinosinusitis with Nasal Polyps in the Phase 3 SINUS-24 and SINUS-52 Trials

被引：0
|
作者：
Bachert, C. [1 ]
Corren, J. [2 ]
Lee, S. E. [3 ]
Zhang, H. [4 ]
Harel, S. [5 ]
Cunoosamy, D. [6 ]
Khan, A. H. [5 ]
Jacob-Nara, J. A. [6 ]
Siddiqui, S. [4 ]
Nash, S. [4 ]
机构：
[1] Univ Ghent, Ghent, Belgium
[2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[3] Univ Pittsburgh, Med Ctr, Dept Otolaryngol Head & Neck Surg, Pittsburgh, PA USA
[4] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[5] Sanofi, Chilly Mazarin, France
[6] Sanofi, Cambridge, MA USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2021年 / 203卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A1343
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS-24 and SINUS-52 trials
    Bachert, Claus
    Corren, Jonathan
    Lee, Stella E.
    Zhang, Haixin
    Harel, Sivan
    Cunoosamy, Danen
    Khan, Asif H.
    Jacob-Nara, Juby A.
    Siddiqui, Shahid
    Nash, Scott
    Rowe, Paul J.
    Deniz, Yamo
    INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY, 2022, 12 (09) : 1191 - 1195
  • [2] Efficacy of dupilumab in chronic rhinosinusitis with nasal polyps and comorbid asthma by baseline biomarkers of type 2 inflammation: SINUS-24 and SINUS-52 phase 3 trials
    Maspero, J. F.
    Bachert, C.
    Canonica, G. W.
    Swanson, B. N.
    Cho, S. H.
    Harel, S.
    Jagerschmidt, A.
    Zhang, M.
    Mao, X.
    Mannent, L. P.
    Amin, N.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2021, 51 (01): : 173 - 174
  • [3] Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52
    Bachert, Claus
    Khan, Asif H. H.
    Lee, Stella E. E.
    Hopkins, Claire
    Peters, Anju T. T.
    Fokkens, Wytske
    Praestgaard, Amy
    Radwan, Amr
    Nash, Scott
    Jacob-Nara, Juby A. A.
    Deniz, Yamo
    Rowe, Paul J. J.
    INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY, 2024, 14 (03) : 668 - 678
  • [4] Dupilumab Reduces Blood, Urine, and Nasal Biomarkers of Type 2 Inflammation in Patients With Chronic Rhinosinusitis With Nasal Polyps in the Phase 3 SINUS-52 Trial
    Bachert, Claus
    Cho, Seong
    Laidlaw, Tanya
    Swanson, Brian
    Harel, Sivan
    Mannent, Leda
    Amin, Nikhil
    Jagerschmidt, Alexandre
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB185 - AB185
  • [5] Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study Results
    Bachert, Claus
    Laidlaw, Tanya M.
    Cho, Seong H.
    Mullol, Joaquim
    Swanson, Brian N.
    Naimi, Souad
    Classe, Marion
    Harel, Sivan
    Jagerschmidt, Alexandre
    Laws, Elizabeth
    Ruddy, Marcella
    Praestgaard, Amy
    Amin, Nikhil
    Mannent, Leda P.
    ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 2023, : 1649 - 1661
  • [6] Rapid and Sustained Effects of Dupilumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps: Analysis of the SINUS-24 and SINUS-52 Phase 3 Trails
    Hellings, P. W.
    Peters, A.
    Chaker, A. M.
    Heffler, E.
    Zhang, H.
    Daizadeh, N.
    Nash, S.
    Khan, A. H.
    Siddiqui, S.
    Jacob-Nara, J. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [7] Baseline Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma from the Pooled Populations of the SINUS-24 and SINUS-52 Dupilumab Phase 3 Trials
    Desrosiers, M.
    Mullol, J.
    Forwith, K.
    Gevaert, P.
    Maspero, J. F.
    Zhang, M.
    Mao, X.
    Amin, N.
    Mannent, L. P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [8] Dupilumab Provides Early and Durable Improvement of Symptoms in Patients with Chronic Rhinosinusitis with Nasal Polyps: Results from the SINUS-24 and SINUS-52 Phase 3 Trials
    Gevaert, P.
    Lee, S. E.
    Settipane, R.
    Wagenmann, M.
    Msihid, J.
    Siddiqui, S.
    Nash, S.
    Jacob-Nara, J. A.
    Khan, A. H.
    Kamat, S.
    Chuang, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [9] Dupilumab Treatment Improves Sense of Smell in Patients With Chronic Rhinosinusitis With Nasal Polyps - Pooled Results From the SINUS-24 and SINUS-52 Phase 3 Trials
    Mullol, Joaquim
    Han, Joseph
    Bosso, John
    Mannent, Leda
    Amin, Nikhil
    Cho, Seong
    Bachert, Claus
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB169 - AB169
  • [10] DUPILUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS AND COMORBID ASTHMA: SINUS-24/SINUS-52 TRIALS
    Gevaert, P.
    Bachert, C.
    Desrosiers, M.
    Mullol, J.
    Maspero, J.
    Zhang, M.
    Mao, X.
    Kamat, S.
    Khan, A.
    Amin, N.
    Staudinger, H.
    Mannent, L.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S58 - S59
12345